Sami A J, Wallis O C, Wallis M
Biochemistry Laboratory, School of Biological Sciences, University of Sussex, Brighton, East Sussex BN1 9QG, UK.
J Mol Endocrinol. 1999 Aug;23(1):97-106. doi: 10.1677/jme.0.0230097.
A number of analogues of ovine growth hormone (GH), in which regions of the hormone had been deleted, were produced by site-directed mutagenesis, and characterised by radioimmunoassays and radioreceptor assays. These analogues were based on a previously described variant (oGH1) in which an 8-residue extension replaces the N-terminal alanine of pituitary-derived ovine GH. Three analogues with deletions near the N-terminus were studied, with shorter extensions of 7 or 1-2 residues (oGH14, oGH5) or with the N-terminal sequence Ala-Phe-Pro- of pituitary-derived ovine GH replaced by Thr-Met-Ile-Thr- (oGH11). These modifications had little effect on potency in radioimmunoassays based on a polyclonal antibody and five different monoclonal antibodies (MABs), or in a radioreceptor assay, indicating that the N-terminal sequence was not included in the epitope binding to any of the monoclonal antibodies, or a major epitope binding to the polyclonal antibody, or in receptor binding site 1. A variant in which residues 133-139 were deleted retained full binding to 4 of the 5 MABs, suggesting correct folding, but markedly reduced binding to MAB OA16, suggesting that the epitope for this MAB includes some or all of these residues. This variant also failed to displace about 35% of labelled hormone from the polyclonal antibody studied, suggesting that residues 133-139 may be involved in a major epitope for this antibody. This variant showed slightly lower receptor binding activity than ovine GH. Two other deletion variants - oGH1Delta33-46 (equivalent to the naturally occurring 20K variant of human GH) and oGH1Delta180-191 (lacking the C-terminal 12 residues) showed poor folding efficiency and solubility, and low binding to all MABs except OA15, which has a linear epitope. The results suggest that these variants were incorrectly folded, but interestingly they did retain some activity in the receptor-binding assay (respectively about 5% and 0.5% of the activity of ovine GH itself).
通过定点诱变产生了许多绵羊生长激素(GH)类似物,这些类似物中激素的某些区域已被删除,并通过放射免疫测定和放射受体测定进行了表征。这些类似物基于先前描述的变体(oGH1),其中一个8个残基的延伸取代了垂体来源的绵羊GH的N端丙氨酸。研究了三种在N端附近有缺失的类似物,其延伸较短,分别为7个或1 - 2个残基(oGH14、oGH5),或者垂体来源的绵羊GH的N端序列Ala - Phe - Pro - 被Thr - Met - Ile - Thr - 取代(oGH11)。这些修饰对基于多克隆抗体和五种不同单克隆抗体(MABs)的放射免疫测定,以及对放射受体测定中的效力影响很小,这表明N端序列不包含在与任何单克隆抗体结合的表位中,也不包含在与多克隆抗体结合的主要表位中,或者在受体结合位点1中。一个缺失了133 - 139位残基的变体与5种MABs中的4种保持完全结合,表明折叠正确,但与MAB OA16的结合明显减少,这表明该MAB的表位包括这些残基中的一些或全部。该变体也未能从所研究的多克隆抗体中置换出约35%的标记激素,这表明133 - 139位残基可能参与了该抗体的主要表位。该变体的受体结合活性略低于绵羊GH。另外两个缺失变体——oGH1Delta33 - 46(相当于天然存在的人GH的20K变体)和oGH1Delta180 - 191(缺少C端的12个残基)显示出较差的折叠效率和溶解性,并且除了具有线性表位的OA15外,与所有MABs的结合都很低。结果表明这些变体折叠错误,但有趣的是它们在受体结合测定中确实保留了一些活性(分别约为绵羊GH本身活性的5%和0.5%)。